AMRX in the 13F filings
Amneal Pharmaceuticals Inc · CUSIP 03168L105
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 22 Jan 2026
- Managers listing it
- 30
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 4 listed it in both
- Shares listed
- 28,645,747
- combined, among listed positions
- Reported value
- $361m
- combined, at the quarter end
Among the 92 comparable managers: 17 buyers (opened or added shares) and 14 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +389,873.
Managers listing AMRX in Q4 2025
30 of 30 holders
Largest increases and reductions, by shares
Increases
- D. E. Shaw & Co.existing position · 2,661,854 shares now+1,096,643
- Citadel Advisors LLCexisting position · 6,175,737 shares now+446,438
- Voloridge Investment Management LLCexisting position · 563,680 shares now+328,253
- Two Sigma Investments LPexisting position · 301,028 shares now+231,494
- AllianceBernstein LPexisting position · 529,846 shares now+217,340
Reductions
- Acadian Asset Management LLCexisting position · 2,021,171 shares now-569,351
- Squarepoint Ops LLCexisting position · 168,633 shares now-371,575
- Man Group PLCexisting position · 62,826 shares now-274,455
- Arrowstreet Capital LPexisting position · 1,090,424 shares now-207,338
- Quantbot Technologies LPexisting position · 33,130 shares now-118,390
New positions and exits
New (0)
No new position among listed positions.
Exited (2)
- Walleye Capital LLCwas $8.0m
- Winton Group Ltdwas $304k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2018 | 3 | $226m | n.a. | n.a. |
| Q3 2018 | 6 | $588m | n.a. | n.a. |
| Q4 2018 | 3 | $514m | n.a. | n.a. |
| Q1 2019 | 3 | $514m | n.a. | n.a. |
| Q2 2019 | 1 | $24m | n.a. | n.a. |
| Q4 2020 | 1 | $2k | n.a. | n.a. |
| Q1 2021 | 3 | $30m | n.a. | n.a. |
| Q2 2021 | 2 | $9.3m | n.a. | n.a. |
| Q3 2021 | 2 | $20m | n.a. | n.a. |
| Q4 2021 | 2 | $16m | n.a. | n.a. |
| Q1 2022 | 2 | $13m | n.a. | n.a. |
| Q2 2022 | 1 | $11m | n.a. | n.a. |
| Q3 2023 | 2 | $879k | n.a. | n.a. |
| Q4 2023 | 1 | $506k | 0 | 1 |
| Q1 2024 | 2 | $4.7m | 2 | 0 |
| Q2 2024 | 2 | $13m | 2 | 1 |
| Q3 2024 | 3 | $23m | 3 | 0 |
| Q4 2024 | 2 | $14m | 2 | 1 |
| Q1 2025 | 4 | $39m | 4 | 0 |
| Q2 2025 | 3 | $28m | 2 | 1 |
| Q3 2025 | 4 | $37m | 2 | 2 |
| Q4 2025 | 5 | $85m | 17 | 14 |
| Q1 2026 | 7 | $78m | 14 | 19 |
| Q2 2026 | 4 | $101m | 11 | 19 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
AMRX and LLY →AMRX and JNJ →AMRX and VRTX →Choose a stock to compare with AMRX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own AMRX, latest filings →Back to the 13F Explorer →